Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $31.45M fell 12.5% year over year, ahead of the -14.3% change in trailing-twelve-month research & development. Sequentially, it rose 7.2% from the prior quarter. Over 3 fiscal years it compounded at -5.0% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -12.5% holds above the trailing-twelve-month pace of -14.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 142.02M USD
- Year-over-year change
- -17.1%
- 4-year CAGR
- +3.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 142.02M | -17.1% |
| FY2024 | 2024-12-31 | 171.24M | -8.1% |
| FY2023 | 2023-12-31 | 186.34M | +12.5% |
| FY2022 | 2022-12-31 | 165.57M | +32.0% |
| FY2021 | 2021-12-31 | 125.48M | — |
Research & Development vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 research & development of $137.53M is the 3rd highest of the 10 companies compared; the peer median is $94.92M.
- Its year-over-year change of -14.3% is the 7th highest of 9, against a peer median of +17.1%.
- Over three fiscal years its annual growth of -5.0% compares with a peer median of +15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $124.71M | +42.2% | +15.6% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $58.13M | +16.8% | +6.7% | — | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| LTM Mar 2026 | $10.04M | -71.3% | -23.4% | — | |
| Peer median (excluding RCKT) | $94.92M | +17.1% | +15.6% | 1532.7% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.03M |
| Gross Profit | 0 | 0 | 0 | 0 | (11.03M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 125.48M | 165.57M | 186.34M | 171.24M | 142.02M |
| Selling, General & Admin | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| Operating Expenses | 167.25M | 224.34M | 259.66M | 273.21M | 217.49M |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| EBITDA | (157.81M) | (213.69M) | (236.62M) | (247.49M) | (210.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (167.25M) | (224.34M) | (259.66M) | (273.21M) | (228.52M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M |
| Interest Expense | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M |
| Other Income / Expenses | (1.82M) | 2.48M | 14.06M | 14.46M | 5.39M |
| Income Before Tax | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| EPS (Diluted) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| Weighted Avg Shares | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Weighted Avg Shares (Diluted) | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.